The purpose of this study is to evaluate the use of a non-contrast MRI for the assessment of the vasculature of the lower extremity anatomical regions. Patients eligible for this study must have been referred for a clinical contrast enhanced CT scan or an invasive catheter angiography. The overall image quality and diagnostic accuracy of the non-contrast MRI will be compared to current clinical standards of care, such as contrast enhanced MRI, CT, and invasive angiography.
This study will examine changes in brain architecture that are associated with vascular parkinsonism, in comparison to Parkinson's disease. We will do this by using advanced imaging techniques to compare brain structure between subjects with vascular parkinsonism and Parkinson's disease.
The Actelion SOPRANO study is a prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group Phase II study to evaluate the safety and effect of macitentan on pulmonary vascular resistance in subjects with pulmonary hypertension after left ventricular assist device (LVAD) implantation. Male and female patients 18 years of age or older who have had surgical implantation of LVAD may be eligible to participate in this study.
8 Richland Medical Park
Columbia, SC 29203
Study Site Principal Investigator Contact Information:
Patrick McCann, MD at 803-434-3800
This study is being conduct to assess the safety and effectiveness of a Study Sevice,GORE® EXCLUDER® Conformable AAA Endoprosthesis, in patient's with an aneurysm in their abdominal aorta. In this research study, the Study Device will be placed inside the abdominal aorta (in the approximate area of the belly button) and the Study Device will extend into both leg arteries. The Study Device will block the aneurysm (the weakened and bulging part of the artery) in the abdominal aorta from blood flow while maintaining blood flow to the arteries in the legs. Information will be collected on the performance of the Study Device for up to five (5) years.
The PREMIERS study is a proposal for conducting an adequately powered two center phase III randomized controlled trial to test whether intensive periodontal treatment reduces the risk of recurrent vascular events among ischemic stroke and TIA survivors. The study uses the resources in both states including established
dental centers, Joint Commission Certified Stroke Centers, the Schools of Public Health, and the Institute for Partnerships to Eliminate Health Disparities. The proposal addresses specific issues with regards to recruitment of African-American and rural stroke/TIA patients advocating the use of culturally appropriate strategies to educate the study subjects regarding stroke, periodontal disease and the periodontal stroke link.
The study proposes to utilize economic evaluation of the periodontal intervention from the budgetary
perspective. The focus will be on the financial sustainability of providing aggressive periodontal therapy (with
certain, although relatively low expenditures) in exchange for a reduction of uncertain recurrent vascular events
that may require high cost emergency department utilization and/or inpatient care. The sustainability of the
proposed intervention after the completion of the project is integrally linked to the health economic assessment
to show the health care cost savings. By integration with a rural primary care center, with an African American
majority and households with average incomes below the state average, the study ensures that the proposed
intervention to reduce stroke disparity is applicable to this target population.
Individuals with venous leg and diabetic foot ulcers often find these ulcers take a long time to heal and when they do, sometimes they come back. These ulcers can be quite painful making it hard to work, sleep and go about one's day to day activities. You will be asked to do a self-care routine of taking the temperature of the skin where the leg or foot ulcer just healed with a special thermometer and applying a small cooling gel patch over this skin. We want to know if this routine will prevent the ulcer from coming back, help you to become more active, and improve the quality of your life.
This study will test a low intensity foot exercise program for people with lower leg ulcers and who have problems with walking to see if it improves the condition of the legs. A small activity monitoring tracker called an accelerometer will be placed on the foot during the exercises that are to be done in the home for about 6 weeks. The tracker sends movement information to a cell phone that lets you and your doctor know about improvements in the foot movements. Better foot movements help condition the muscles and joints and may improve activity such as walking and getting up from a chair.
Design and Procedures
The objective of this research proposal is to compare treatment strategies currently being used to treat an uncommon condition, symptomatic CAD, by conducting a prospective longitudinal observational study using a patient-centered web-based data capture. We will conduct several comparative research protocols prioritized by CAD survivor focus groups and surveys. The prospective component of COMPASS Pilot will utilize both the i2b2 and RFA database combined with additional follow up interviews of 100 CAD survivors at 6 months and 12 months after discharge, for a combined cohort to obtain detailed information on patient ?reported outcomes.
The proposed project will use a cohort study design (N=100) with web-based data capture to acquire high quality information. Detailed observational data will be collected and used in propensity score analysis to adjust for the baseline differences in treatment groups. This includes differences arising from selection bias and measured confounders. The propensity score based adjustment of these differences will result in a better estimate of the effect size. A user friendly, web-based data capture tool will facilitate the identification of clinically significant outcomes in a larger number of patients. Once validated, the methodology can be used to obtain evidence of comparative effectiveness that will aid decision-making in treatment of other rare neurological diseases where RCTs are unfeasible.
The following are candidate outcomes of interest in COMPASS Pilot for both therapeutic areas:
? "Home-time" (days alive and at home)
? Stroke/TIA readmission
? All-cause readmission
? Cardiovascular readmission
? Bleeding readmission
The COMPASS Pilot study plans on inclusion of a diverse study population with respect to age, gender, race, ethnicity, geography, or clinical status. Specific patient selection criteria:
1. Patients who are at least 18 years of age.
2. Extracranial carotid or vertebral artery dissection with symptom onset within the last ninety days. Patients will be included with ipsilateral TIA or stroke and ipsilateral Horner's syndrome or neck pain with known onset.
3. Imaging evidence of definite or probable dissection on magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA), computed tomography angiography (CTA) or ultrasound (patients can be initially randomized on ultrasound alone but subsequent MR or CTA confirmation is needed).
4. Patient or patient's legally appointed representative has been informed of the nature of the study, agrees to participation, and has signed an IRB approved consent form.
1. Symptom onset more than ninety days
3. Contraindications to either antiplatelet agents or anticoagulation therapy
4. Patient refusal to consent
5. Patient unable to follow-up for the 12 month period.
The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3 months) anticoagulation in children with first-episode acute venous thrombosis. The first stage of the trial has consisted of a pilot/feasibility component which has now been completed.
Male and female patients who meet the following criteria may take part in this study:
1. Children (birth to less than 21 years of age) with radiologically-confirmed acute venous thrombosis in the past 30 days
2. In the opinion of the investigator, the venous thrombosis was a provoked (i.e., non-spontaneous) event (e.g.: hospitalization; Central venous catheterization; infection; dehydration; surgery; trauma; immobility; use of estrogen-containing oral contraceptive pills; flare of autoimmune/rheumatologic condition).
1. Prior episode of VTE
2. Malignancy that, in the opinion of the treating oncologist, is not in remission, or for which chronic anticoagulation is being administered/anticipated to be initiated within 6 months (note: remission may exist on or off anti-neoplastic therapy)
3. Systemic lupus erythematosus
4. Pulmonary embolism that is not accompanied by DVT or is more proximal than segmental branches of the pulmonary artery
5. Use of, or intent to use, thrombolytic therapy
6. History of congenital cardiac disease for which chronic anticoagulation is being administered/ anticipated to be initiated within 6 months (e.g., for select patients or centers, in the setting of a single or hypoplastic ventricle or surgically-established cardiac shunt)
7. Moderate/severe anticoagulant deficiency as defined by any one of the following:
a. protein C s Hospital
7 Richland Medical Park
Columbia, SC 29203
Study Site Principal Investigator Contact Information:
Stuart L. Cramer, DO at 803-434-3533
Blood samples from patients admitted to the intensive care unit with a severe infection (sepsis) will be analyzed for markers of gene regulation called micro RNA. Micro RNA levels will be compared between patients with sepsis, patients with other non-septic critical illness and healthy individuals. Micro RNA levels will be analyzed to determine if they correlate with hospitalization outcomes.